

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 6, 2017

Adam Craig President and Chief Executive Officer CTI BioPharma Corp. 3101 Western Avenue, Suite 600 Seattle, Washington 98121

Re: CTI BioPharma Corp.
Preliminary Proxy Statement on Schedule 14A
Filed November 28, 2017
File No. 000-28386

Dear Dr. Craig:

We have limited our review of your filing to those issues we have addressed in our comment.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A filed November 28, 2017

<u>Proposal 1: Approval of Delaware Reincorporation</u>

<u>Comparison of Shareholder Rights Before and After the Reincorporation, page 12</u>

1. Please expand your disclosure to compare shareholders' rights pursuant to the exclusive forum provision in Article XI of the Certificate of Incorporation to be filed in Delaware with shareholders' current rights in Washington.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Adam Craig CTI BioPharma Corp. December 6, 2017 Page 2

Please contact Irene Paik at 202-551-6553 or Mary Beth Breslin at 202-551-3625 with any questions.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Brophy Christensen - O'Melveny &Myers LLP